- Home
- NDRA vs OGEN Comparison
NDRA vs OGEN Comparison
Compare NDRA & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDRA
- OGEN
- Stock Information
- Founded
- NDRA 2007
- OGEN 1996
- Country
- NDRA United States
- OGEN United States
- Employees
- NDRA N/A
- OGEN N/A
- Industry
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- NDRA Health Care
- OGEN Health Care
- Exchange
- NDRA Nasdaq
- OGEN Nasdaq
- Market Cap
- NDRA 4.6M
- OGEN 5.4M
- IPO Year
- NDRA 2017
- OGEN N/A
- Fundamental
- Price
- NDRA $5.01
- OGEN $1.29
- Analyst Decision
- NDRA Strong Buy
- OGEN
- Analyst Count
- NDRA 1
- OGEN 0
- Target Price
- NDRA $38.00
- OGEN N/A
- AVG Volume (30 Days)
- NDRA 798.9K
- OGEN 206.2K
- Earning Date
- NDRA 11-14-2025
- OGEN 11-11-2025
- Dividend Yield
- NDRA N/A
- OGEN N/A
- EPS Growth
- NDRA N/A
- OGEN N/A
- EPS
- NDRA N/A
- OGEN N/A
- Revenue
- NDRA N/A
- OGEN N/A
- Revenue This Year
- NDRA N/A
- OGEN N/A
- Revenue Next Year
- NDRA N/A
- OGEN N/A
- P/E Ratio
- NDRA N/A
- OGEN N/A
- Revenue Growth
- NDRA N/A
- OGEN N/A
- 52 Week Low
- NDRA $2.90
- OGEN $1.01
- 52 Week High
- NDRA $12.49
- OGEN $18.90
- Technical
- Relative Strength Index (RSI)
- NDRA 41.38
- OGEN 48.27
- Support Level
- NDRA $4.58
- OGEN $1.26
- Resistance Level
- NDRA $5.43
- OGEN $1.34
- Average True Range (ATR)
- NDRA 0.69
- OGEN 0.07
- MACD
- NDRA -0.24
- OGEN -0.01
- Stochastic Oscillator
- NDRA 8.19
- OGEN 20.00
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.